Rates of HIV-associated dementia have decreased from approximately 50% in the pre-cART era to 2% currently. However, roughly 50% of patients treated with cART have the milder forms of HIV-associated neurocognitive disorder (HAND).
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
According to the United States Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, preliminary data from 2017 show that gay, bisexual, and other men who have sex with men accounted for 67% of incident diagnoses of HIV.
Diagnosing HIV using rapid screening test may not be reliable in HIV-1 controllers, a rare group of individuals living with HIV who maintain HIV viremia at extremely low or even undetectable levels in the absence of antiretroviral treatment.
Investigators analyzed the virologic efficacy and metabolic effect of dolutegravir-based therapy combined with NRTIs in substitution of protease inhibitor-based therapy in patients with a history of failure or intolerance to first-line combination ART.
Researchers examined the prevalence of HIV drug resistance patterns among HIV-infected infants using 3 nationally representative surveys in South Africa that evaluated the effectiveness of national programs to prevent mother-to-child transmission of HIV.
Researchers assessed the characteristics of children who tested positive for HIV diagnosed with HIV infection at the primary healthcare level, across all provinces of South Africa, their attendance at study-specific exit interviews, and their reported uptake of HIV-related care.
A new treatment-decision score for the diagnosis of TB in children with HIV performed well, and when used in an algorithm may facilitate prompt treatment decision making for children at a high risk for mortality.
HIV treatment and virologic failure, and sustained viral response at week 12 or 24 were not different among patients who did or did not undergo a switch in their antiretroviral therapy regimen prior to DAA treatment.